Structure Therapeutics Partners With Unlearn to Analyze Oral Obesity Drug Data Using AI-Generated Digital Twins

Key Points

• Unlearn will apply AI modeling to existing data from Structure Therapeutics’ completed ACCESS open-label extension study of aleniglipron.
• The analysis will estimate how participants might have fared without treatment and compare those estimates with observed outcomes.
• Structure said the work is separate from its clinical development program and may provide additional context for longer-term findings.
• Results are scheduled for presentation at ObesityWeek, November 14–17, 2026.
• The announcement did not disclose financial terms or findings from the analysis.

Structure Therapeutics (Nasdaq: GPCR) is collaborating with Unlearn AI on a retrospective analysis of its investigational obesity treatment, aleniglipron.

The once-daily oral GLP-1 receptor agonist will be evaluated using anonymized patient data already collected in the completed ACCESS open-label extension study. The collaboration does not involve a newly announced clinical trial.

AI Analysis Aims to Add Context to Longer-Term Results

Unlearn will generate model-based estimates of what participants’ outcomes might have been without the investigational treatment. The company calls these estimates “digital twins.”

Comparing those estimates with actual study outcomes may provide additional context for interpreting aleniglipron’s longer-term findings. The announcement does not present the modeled outcomes as observed results from an untreated group.

Structure’s chief medical officer, Dr. Blai Coll, emphasized that the analysis is separate from the company’s clinical development program and may supplement its broader evaluation of aleniglipron.

ObesityWeek Presentation Is the Next Milestone

Data from the analysis will be included in a poster titled “Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension” at ObesityWeek in National Harbor, Maryland, November 14–17.

The announcement did not provide numerical findings or indicate changes to development timelines.

Investor Takeaway

The collaboration offers a new way to examine existing aleniglipron data, but it is not itself a new efficacy readout or regulatory milestone.

For GPCR investors, the upcoming poster is the immediate item to watch: whether the modeling adds useful context to the observed results and how clearly its assumptions and limitations are explained. No financial contribution or change to the drug’s development plan was disclosed.